169 related articles for article (PubMed ID: 11796335)
1. Strong antifungal activity of SS750, a new triazole derivative, is based on its selective binding affinity to cytochrome P450 of fungi.
Matsumoto M; Ishida K; Konagai A; Maebashi K; Asaoka T
Antimicrob Agents Chemother; 2002 Feb; 46(2):308-14. PubMed ID: 11796335
[TBL] [Abstract][Full Text] [Related]
2. A new triazole, voriconazole (UK-109,496), blocks sterol biosynthesis in Candida albicans and Candida krusei.
Sanati H; Belanger P; Fratti R; Ghannoum M
Antimicrob Agents Chemother; 1997 Nov; 41(11):2492-6. PubMed ID: 9371355
[TBL] [Abstract][Full Text] [Related]
3. Inhibition and interaction of cytochrome P450 of Candida krusei with azole antifungal drugs.
Venkateswarlu K; Denning DW; Kelly SL
J Med Vet Mycol; 1997; 35(1):19-25. PubMed ID: 9061581
[TBL] [Abstract][Full Text] [Related]
4. Mechanism of fluconazole resistance in Candida krusei.
Orozco AS; Higginbotham LM; Hitchcock CA; Parkinson T; Falconer D; Ibrahim AS; Ghannoum MA; Filler SG
Antimicrob Agents Chemother; 1998 Oct; 42(10):2645-9. PubMed ID: 9756770
[TBL] [Abstract][Full Text] [Related]
5. Comparison of D0870, a new triazole antifungal agent, to fluconazole for inhibition of Candida albicans cytochrome P-450 by using in vitro assays.
Venkateswarlu K; Denning DW; Manning NJ; Kelly SL
Antimicrob Agents Chemother; 1996 Jun; 40(6):1382-6. PubMed ID: 8726005
[TBL] [Abstract][Full Text] [Related]
6. Antifungal activities of R-135853, a sordarin derivative, in experimental candidiasis in mice.
Kamai Y; Kakuta M; Shibayama T; Fukuoka T; Kuwahara S
Antimicrob Agents Chemother; 2005 Jan; 49(1):52-6. PubMed ID: 15616275
[TBL] [Abstract][Full Text] [Related]
7. In vitro and in vivo antifungal activities of TAK-456, a novel oral triazole with a broad antifungal spectrum.
Tsuchimori N; Hayashi R; Kitamoto N; Asai K; Kitazaki T; Iizawa Y; Itoh K; Okonogi K
Antimicrob Agents Chemother; 2002 May; 46(5):1388-93. PubMed ID: 11959573
[TBL] [Abstract][Full Text] [Related]
8. In vitro and in vivo antifungal activities of ER-30346, a novel oral triazole with a broad antifungal spectrum.
Hata K; Kimura J; Miki H; Toyosawa T; Nakamura T; Katsu K
Antimicrob Agents Chemother; 1996 Oct; 40(10):2237-42. PubMed ID: 8891121
[TBL] [Abstract][Full Text] [Related]
9. Structural analyses of
Hargrove TY; Friggeri L; Wawrzak Z; Qi A; Hoekstra WJ; Schotzinger RJ; York JD; Guengerich FP; Lepesheva GI
J Biol Chem; 2017 Apr; 292(16):6728-6743. PubMed ID: 28258218
[TBL] [Abstract][Full Text] [Related]
10. In vitro and in vivo antifungal activities of FX0685, a novel triazole antifungal agent with potent activity against fluconazole-resistant Candida albicans.
Takahata S; Okutomi T; Ohtsuka K; Hoshiko S; Uchida K; Yamaguchi H
Med Mycol; 2005 May; 43(3):227-33. PubMed ID: 16010849
[TBL] [Abstract][Full Text] [Related]
11. Origin of differences in susceptibility of Candida krusei to azole antifungal agents.
Marichal P; Gorrens J; Coene MC; Le Jeune L; Vanden Bossche H
Mycoses; 1995; 38(3-4):111-7. PubMed ID: 7477085
[TBL] [Abstract][Full Text] [Related]
12. Design, synthesis and antifungal evaluation of 1-(2-(2,4-difluorophenyl)-2-hydroxy-3-(1H-1,2,4-triazol-1-yl)propyl)-1H-1,2,4-triazol-5(4H)-one.
Jiang Y; Cao Y; Zhang J; Zou Y; Chai X; Hu H; Zhao Q; Wu Q; Zhang D; Jiang Y; Sun Q
Eur J Med Chem; 2011 Jul; 46(7):3135-41. PubMed ID: 21354675
[TBL] [Abstract][Full Text] [Related]
13. Antifungal drug resistance in pathogenic fungi.
Vanden Bossche H; Dromer F; Improvisi I; Lozano-Chiu M; Rex JH; Sanglard D
Med Mycol; 1998; 36 Suppl 1():119-28. PubMed ID: 9988500
[TBL] [Abstract][Full Text] [Related]
14. Heterologous Expression of Full-Length Lanosterol 14α-Demethylases of Prominent Fungal Pathogens Candida albicans and Candida glabrata Provides Tools for Antifungal Discovery.
Keniya MV; Ruma YN; Tyndall JDA; Monk BC
Antimicrob Agents Chemother; 2018 Nov; 62(11):. PubMed ID: 30126959
[TBL] [Abstract][Full Text] [Related]
15. The G464S amino acid substitution in Candida albicans sterol 14alpha-demethylase causes fluconazole resistance in the clinic through reduced affinity.
Kelly SL; Lamb DC; Loeffler J; Einsele H; Kelly DE
Biochem Biophys Res Commun; 1999 Aug; 262(1):174-9. PubMed ID: 10448088
[TBL] [Abstract][Full Text] [Related]
16. [Antifungal susceptibility profiles of Candida species to triazole: application of new CLSI species-specific clinical breakpoints and epidemiological cutoff values for characterization of antifungal resistance].
Karabıçak N; Alem N
Mikrobiyol Bul; 2016 Jan; 50(1):122-32. PubMed ID: 27058336
[TBL] [Abstract][Full Text] [Related]
17. Candida and candidaemia. Susceptibility and epidemiology.
Arendrup MC
Dan Med J; 2013 Nov; 60(11):B4698. PubMed ID: 24192246
[TBL] [Abstract][Full Text] [Related]
18. In vitro and in vivo activities of HQQ-3, a new triazole antifungal agent.
Zhao JX; Cao YY; Quan H; Liu CM; He QQ; Wu QY; Gao PH; Cao YB; Liu WX; Jiang YY
Biol Pharm Bull; 2006 Oct; 29(10):2031-4. PubMed ID: 17015946
[TBL] [Abstract][Full Text] [Related]
19. In-vitro activity of D0870, a new triazole antifungal drug, in comparison with fluconazole and itraconazole against Aspergillus fumigatus and Candida krusei.
Venkateswarlu K; Denning DW; Kelly SL
J Antimicrob Chemother; 1997 Jun; 39(6):731-6. PubMed ID: 9222042
[TBL] [Abstract][Full Text] [Related]
20. In vitro and in vivo antifungal activities of aminopiperidine derivatives, novel ergosterol synthesis inhibitors.
Hata M; Yoshida K; Ishii C; Otani T; Ando A
Biol Pharm Bull; 2010; 33(3):473-6. PubMed ID: 20190412
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
